We aimed to identify miRNAs whose expression levels in fetal tissues are altered by exposure to a diabetic milieu and elucidate the impact on target protein expression. Gestational diabetes mellitus (GDM) affects both immediate and future disease risk in the offspring. We hypothesized that GDM alters miRNA expression in human umbilical vein endothelial cells (HUVECs) that may influence metabolic processes. A cross-sectional design compared differences in miRNA expression in HUVECs and target protein abundance in placentae between infants of women with GDM (IGDM) and infants born to normoglycaemic controls. miRNAs were identified using microarray profiling and literature review and validated by quantitative PCR (qPCR). In vitro transfection studies explored the impact of the miRNA on target protein expression. Expression of seven miRNA species, miR-30c-5p, miR-452-5p, miR-126-3p, miR-130b-3p, miR-148a-3p, miRlet-7a-5p and miR-let-7g-5p, was higher in the HUVECs of IGDM. Abundance of the catalytic subunit of AMP-activated protein kinase α1 (AMPKα1) was decreased in the HUVECs and BeWo cells (transformed trophoblast cell line) transfected with miR-130b and miR-148a mimics.
INTRODUCTION
The impact of maternal diabetes on future metabolic health of the offspring is well described [1] [2] [3] . The risk of a child developing Type 2 diabetes mellitus (T2DM) is several times higher when the mother has diabetes mellitus (DM) compared with a child born to a mother with euglycaemia and is related to fetal exposure to DM [1] . In the Pima Indians, Dabelea et al. [2] reported a 25% prevalence of T2DM among 78 youths aged 15-19 years exposed to DM in utero, and exposure to DM in utero was the strongest single predictor for DM in those children. Furthermore, children born after the mother's diagnosis of DM had nearly four times greater risk of developing DM themselves compared with siblings born prior to the mother's diagnosis. This implies that it is exposure to the diabetic milieu per se, and not just the transmission of diabetogenic genes, that increases the risk of developing DM [3] .
Maternal DM has also been shown to have significant effects during early childhood. Vohr and co-workers [4, 5] found that infants of women with GDM (gestational DM) (IGDM) born large for gestational age have increased adiposity at 1, 4 and 7 years and develop metabolic syndrome by age 11 years. Our group has shown that infants of women with DM (gestational and Type 2) have reduced resting energy expenditure and fat oxidation at 1 month of age, even when body mass and composition are unaffected [6] . These studies demonstrate that the prenatal environment influences postnatal growth and metabolism, but the mechanisms involved remain poorly understood. miRNAs are emerging as important regulatory molecules for metabolic processes such as carbohydrate and lipid metabolism and may contribute to the pathogenesis of DM and its complications [7, 8] . miRNAs are small non-coding RNAs that modulate biological processes, typically by repressing translation of targeted mRNAs or causing degradation of mRNAs [9] .
Because hyperglycaemia has been shown to alter miRNA expression in pancreas, adipocyte, liver and vascular endothelium [10] , we hypothesized that miRNAs could be a means by which maternal DM influences offspring metabolism and adiposity. Thus, the aim of the present study was to identify relevant miRNAs that are differentially expressed in fetal tissue of the offspring of mothers with GDM and normoglycaemic (control) mothers.
MATERIALS AND METHODS

Subjects for human umbilical vein endothelial cell (HUVEC) samples
Pregnant women with GDM as defined by the American Diabetes Association [11] and pregnant women with normal glucose tolerance admitted to the labour and delivery suites at the OU Medical Center, were recruited following informed consent. Women were excluded if the infants were small for gestational age, or had a major malformation or chromosome abnormality. They also were excluded if they delivered prior to 37 weeks gestation, had Type 1 diabetes, pre-eclampsia, chronic hypertension, renal disorders or a smoking history of more than five cigarettes per day during pregnancy. Informed written consent was obtained from each participant and the study was approved by the Institutional Review Board at OUHSC.
Subjects for placenta samples
Placental samples were obtained from self-identified Native American and Hispanic women with GDM or normoglycaemic pregnancies whose offspring were enrolled at birth into a prospective longitudinal study on the impact of in utero exposure to DM on postnatal growth. Subjects were recruited from the OU Medical Center, the Chickasaw Nation Medical Center and the Choctaw Nation Health Care Center. Written consent was obtained from the mother in accordance with the University of Oklahoma Health Sciences Center, Chickasaw Nation of Oklahoma or Choctaw Nation of Oklahoma Institutional Review Board, each of which approved the study. Diagnostic methods and inclusion/exclusion criteria were the same as for the HUVEC cohort, except that enrolment for this group was restricted to Native American and Hispanic women.
HUVEC isolation
Umbilical cords were stored at 4°C and processed within 24 h of delivery. HUVECs were isolated as previously described by Jaffe et al. [12] with some modifications (http:// vrd.bwh.harvard.edu/core_facilities/harvest_huvec.html). The umbilical vein was cannulated at both ends of the cord specimen, flushed with Dulbecco's phosphate-buffered saline (DPBS) without Ca/Mg (Gibco/Life Technologies) and incubated with 0.1% collagenase A solution (Roche Applied Science) in DPBS with Ca/Mg (Gibco/Life Technologies) at 37°C for 15 min. Isolated HUVECs were washed and either processed for cell culture as described below or immediately disrupted with Qiazol Lysis Reagent (Qiagen) according to the manufacturer's protocol and stored at −80°C until RNA extraction. membrane was removed and the remaining tissue washed with ice-cold saline, blotted dry and stored at −80°C. Only the fetal-side placenta samples were used in this analysis.
Cell culture
HUVECs were identified morphologically by their cobble-stone appearance by microscopy and their vascular endothelial nature confirmed by immuno-staining for von Willebrand factor (vWF; Anti-Human von Willebrand factor; Sigma-Aldrich). More than 90% of the cells were vWF-positive. Primary cultures of control HUVECs were established in fibronectin-coated (Sigma-Aldrich) vessels as described by Baudin et al. [13] with modification. Growth medium consisted of 1× M199 medium (Gibco/Life Technologies) buffered with 7% sodium bicarbonate solution and 1 M HEPES (Fisher Scientific), supplemented with 0.2 M L-glutamine, 10000 IU/ml penicillin and 10000 μg/ml streptomycin (Mediatech), 20% heat-inactivated fetal bovine serum (FBS; Mediatech), 50 μg/ml endothelial cell growth supplement (ECGS) from bovine neural tissue (SigmaAldrich) and 100 μg/ml heparin (Grade 1, from porcine intestinal mucosa; Sigma-Aldrich).
Cells were incubated at 37°C in 5% CO 2 /95% air atmosphere saturated with water.
BeWo cells, initiated from malignant gestational choriocarcinoma of the fetal placentae (Sigma-Aldrich) were cultured in Ham's F12 medium (Gibco/Life Technologies) supplemented with 10% FBS (Mediatech), 100 μM MEM non-essential amino acids (Gibco/ Life Technologies), and 0.5% penicillin/streptomycin/amphotericin B (Gibco/Life Technologies). To simulate oxidative stress, the cells were serum starved for 6 h.
Transfection of miRNA mimics
The HUVECs or BeWo cells were transfected with the mirVana ™ miRNA mimics of miR-130b-3p, miR-148a-3p, miR-29b-3p, miR-130b inhibitor, miR-148a inhibitor or mirVana ™ miRNA Mimic Negative Control #1 at a concentration of 20 nM for the HUVECs and 100 nM for the BeWo cells using Lipofectamine RNAiMAX Transfection reagent (Life Technologies) at a concentration of 0.25 μl of reagent per 100 μl of medium according to the manufacturer's protocol. The negative control contains a synthetic miRNA sequence with no known homology to the human transcriptome. At 48 h post-transfection, the cells were harvested. The protein and RNA extracts were analysed by Western blot analysis and quantitative PCR (qPCR) respectively. qPCR was used to confirm transfection of the selected miRNA species (see Figures 2A-2C and 3A-3C).
RNA extraction
Total RNA was extracted from the freshly isolated and cultured HUVECs and BeWo cells using commercially available kits (miRNeasy, Qiagen) according to the manufacturer's instructions. Isolated total RNA was quantified by a NanoDrop ND-1000 spectrophotometer (Thermo Scientific) and presence of miRNA was verified using the small RNA chip on an Agilent 2100 Bioanalyzer (Agilent Technologies).
miRNA microarray analyses
For HUVEC miRNA profiling, samples for three individual IGDM subjects and three aliquots of pooled total RNA from two control pairs matched for infant sex and maternal ethnicity were submitted, allowing the miRNA profiles from three IGDM subjects to be compared with three pools of two control subjects each. Each sample contained 2 μg of total RNA and was analysed by LC Sciences (part number MRA-1001B2, miRBase Version 19 containing 2019 unique mature miRNA probes). Each sample was run on a separate chip.
qPCR analysis
Reverse transcription (RT) was done using the TaqMan MicroRNA Reverse Transcription Kit (Life Technologies) and a pool of miRNA-specific RT primers according to the Applied Biosystems protocol (publication part number 4465407, Life Technologies). Starting material comprised 8 ng of total RNA in the fresh HUVECs and 10 ng in the cultured cells. All qPCR reactions for miRNA validation were performed in triplicate using TaqMan MicroRNA Assays (Life Technologies) and Taq-Man Universal Master Mix II, no UNG (Life Technologies) on the Applied Biosystems 7300 Real-Time PCR System (Applied Biosystems). RNU 48 was used as an endogenous control for all reactions.
Target prediction
Validated web-based software programs, miRTarBase [14] , miRBase [15] and DIANATarBase [16] , were used to identify potential targets of the differentially expressed miRNAs. Preference was given to target mRNAs that had been previously confirmed by reporter assay, Western blot or PCR. The targets were then narrowed to those that were specifically involved in energy metabolism, adipogenesis and endothelial function.
Western blot analysis
The placenta samples and cultured cells (HUVECs and BeWo cells) were lysed and homogenized in protein lysis buffer containing a protease and phosphatase inhibitor cocktail (Pierce Biotechnology; part number 78443). Protein concentrations were measured by BCA assay (Pierce). Protein lysates (30 μg) were subjected to SDS/PAGE (10% gel) and transferred on to polyvinylidene fluoride (PVDF) membrane followed by incubation with antibodies specific for AMP-activated protein kinase α1 (AMPKα1), β-actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Cell Signaling Technology). The proteins of interest were detected by enhanced chemiluminescence (Pierce) and analysed by imaging densitometry.
Statistical methods
Subjects' demographic and anthropometric characteristics were compared by Student's t test or Fisher's exact test as indicated using IBM SPSS Statistics (SPSS Released 2009. PASW Statistics for Windows, Version 18.0. SPSS). Differentially expressed transcripts from the microarray analyses were identified by LC Sciences by Student's t test of transcript signal values. Relative expression by qPCR of individual miRNA species was calculated using the 2 −ΔΔC T method [17] , where RNU48 served as the endogenous control miRNA. Relative expression levels of individual miRNA species were compared between the IGDM and control groups using separate exact permutation tests (SAS PROC NPAR1WAY). For protein analysis, in vitro experiments were normalized to β-actin expression whereas in vivo experiments were normalized to GAPDH or expressed as a ratio of phosphorylated to total Tryggestad et al.
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protein. Means and S.E.M. were calculated, and Student's t test was used for between-group comparisons.
RESULTS
Characteristics of HUVECs study population
Demographic and anthropometric characteristics of the subjects are listed in Table 1 . The IGDM and control groups did not differ with respect to maternal age, body mass index (BMI) or ethnicity, infant birth weight or mode of delivery. However, the proportion of males in the IGDM group exceeded that of the control group. In general, maternal GDM was well controlled during the pregnancy as evidenced by an average haemoglobin A1c (HbA1c) of 5.7% (38.8 mmol/mol) and no difference in the birth weights of their offspring compared with those of the healthy controls. Treatments for GDM and number of mothers on each treatment were as follows: glyburide = 4, insulin = 1 and diet alone = 2.
Characteristics of placentae study population
Demographic and anthropometric characteristics of the subjects are listed in Table 2 . There were no significant differences between the IGDM and control groups with respect to ethnicity, BMI, infant sex or body weight, gestational age or mode of delivery. The mothers with DM were slightly older than the control mothers. In general, maternal DM was well controlled during the pregnancy as evidenced by an average HbA1c of 5.7% (38.8 mmol/ mol). Treatments for GDM and number of mothers on each treatment were as follows: glyburide = 5, insulin = 5, diet alone = 5, metformin = 1.
Microarray analyses of HUVEC miRNA
miRNAs potentially influenced by maternal GDM were sought by first examining the miRNA microarray profile from a subset of IGDM and control HUVECs. Among the approximately 2000 unique miRNA species tested, we selected 32 miRNA species for further study by qPCR (Table 3 ). The selection was based on at least 10% difference in signal strength between the groups, a P-value of 0.05 or less, or evidence from literature that the miRNA species was involved in angiogenesis, glucose metabolism or insulin signalling [18] [19] [20] .
Expression of specific miRNA in HUVEC by qPCR qPCR analyses were performed for each of the 32 miRNA species selected for further validation in individual specimens from the IGDM and control groups. Nineteen of the miRNA species were detectable by qPCR. Quantification of the others was unreliable due to low abundance (CT>35). Among the 19 measurable species, seven (miR-30c-5p, miR-452-5p, miR-126-3p, miR-130b-3p, miR-148a-3p, miR-let-7a-5p and miR-let-7g-5p)
showed increased expression in the IGDM HUVECs compared with the control (Figure 1 ). Although the IGDM group had a preponderance of males, there was no significant difference between control males and females in the abundance of any of the miRNAs examined.
Many of the results obtained by qPCR were consistent with those from the microarray (e.g. miR-130b-3p and miR-148a). Relatively low abundance probably played a role in some cases where discordance between the array and qPCR data was observed (e.g. miR-542-5p).
In other cases, apparent differences probably disappeared when the number of samples was increased for measurement by qPCR. Differences may also reflect methodological distinctions. The qPCR probes are typically very specific (i.e. TaqMan ® ) and detect only a single isoform of the miRNA, whereas microarrays give the accumulative number for all isoforms as the probes will bind to all of them. This could explain the differences that were evident with the miR-let-7 species specifically.
Target prediction
Potential targets for the differentially expressed miRNAs were identified from miRNA databases ( Table 4) . Attention was focused on targets involved in energy metabolism, endothelial function and adipogenesis. AMPKα1, a predicted target of miR-130b-3p, miR-148a-3p and miR-29b-3p (Table 4) , was selected for further study because of its role in energy management (e.g., stimulating glucose uptake and fatty acid oxidation).
AMPKα1 abundance in miRNA overexpression
In the HUVECs transfected with miR-130b and miR-148a, but not miR-29b, AMPKα1 (EC 2.7.11.31) abundance was decreased compared with HUVECs transfected with non-specific control miRNA ( Figures 2D and 2E ). AMPKα1 mRNA abundance in the uncultured HUVECs isolated from the cords was quantified by qPCR and found to not be different in the controls compared with the infants born to mothers with diabetes (results not shown). A lack of difference in the mRNA does not negate the finding of decreased protein expression as changes in miRNA expression may not result in changes in mRNA expression as miRNA function to either degrade mRNA or repress the mRNA from translation.
Similarly, in BeWo cells (a transformed trophoblastic cell line) AMPKα1 abundance was also decreased when transfected with miR-130b-3p and miR-148a-3p, but not miR-29b-3p
( Figures 3D and 3E) . When comparing the seed sequence, the conserved heptametrical sequence in positions 2-7 from the miRNA 5′-end, of miR-29b to miR-130b and miR-148a, the sequence of miR-29b is not an exact match to AMPKα1 [14] . Thus it appears that miR-29b-3p does not target AMPKα1 mRNA in this context despite predicted interaction.
AMPKα1 and downstream target abundance in placenta and BeWo cells
AMPKα1 was decreased in the placentae from IGDM of either sex compared with control placentae (Figure 4 ), but did not differ based on treatment. To reduce variability inherent in samples of both human origin and heterogeneous cell type, we used a larger sample size and matched each IGDM with a control of the same infant sex and gestational age. P-AMPKα1 was also decreased in the placenta of female offspring born to mothers with diabetes, although the ratio of P-AMPKα1 to AMPKα1 was unchanged. Acetyl-CoA carboxylase (ACC) was not different in the placenta from female offspring, but P-ACC was decreased in the placenta of female offspring born to mothers with diabetes ( Figure 5 ). This difference was not seen in the placenta from male offspring (results not shown). It is possible that there is a sex-related difference in the phosphorylation of AMPK in the placenta, but other explanations are also possible. For example, samples were not collected in such a way to preserve the phosphorylation sites that may also have affected results.
In BeWo cells transfected with miR-130b inhibitor, upon serum starvation to simulate oxidative stress, total AMPKα1, p-AMPKα1 and P-ACC were all increased compared with samples that were serum-starved but transfected with miRNA negative control ( Figure 6 ).
DISCUSSION
We have identified seven miRNAs that are increased in HUVECs from IGDM, many of which putatively target components of important metabolic pathways. In addition, we provide evidence for direct effects of miR-130b-3p and miR-148a-3p on AMPKα1 through in vitro studies and demonstrate a reduction in AMPKα1 abundance in vivo in placentae exposed to a diabetic milieu. That these two miRNAs have important roles in metabolic processes is strongly supported by the recent report of Wagschal et al. [21] describing a large genome-wide association study of miRNAs linked to lipid homoeostasis in adults. Of the four miRNAs identified as key regulators of metabolic processes, two (130b, 148a) are in common with the seven reported here.
The targeting of AMPKα1 by miRNAs is of interest because of the central role AMPK plays in metabolic homoeostasis. AMPK is an energy-sensing serine/threonine protein kinase activated by AMP [22, 23] ; the α-subunit (AMPKα1) is the main functional unit of the complex [23] . Upon activation of AMPK, energy-producing mechanisms are stimulated (e.g. glucose uptake and fatty acid oxidation), whereas energy-consuming processes are inhibited (e.g., hepatic glucose production) [22, 24] . These features suggest that a reduction in AMPK activity would lead to physiological characteristics of T2DM, including insulin resistance and decreased fatty acid oxidation. In fact, our group recently reported that fat oxidation was reduced in 1-month-old infants born to mothers with diabetes [6] .
The literature provides additional evidence for the involvement of miRNAs 130b and 148a in metabolic process regulation. miR-148a and miR-130b have been shown to influence lipid and energy metabolism by targeting essential factors involved in lipid and glucose homoeostasis, including the low-density lipoprotein (LDL) receptor [21] , salt-inducible kinase 1 (SIK1) [21] (a regulator of hepatic lipogenesis), peroxisome-proliferator-activated receptor γ co-activator 1α (PGC-1α) [21, 25] (a master regulator of mitochondrial biogenesis and lipid oxidation), as well as AMPK [21] .
The majority of publications referencing the other differentially expressed miRNAs we report relate to cancer biology, with limited assessment of their roles in diabetes, metabolism or pregnancy. miR-126-3p is the most extensively studied. It is decreased in circulation in adults with T2DM [19] , and may be used to predict development of T2DM [26, 27] . In children, plasma levels of miR-126 have been positively associated with BMI and plasma triacylglycerols and very-low-density lipoprotein-cholesterol (VLDL-C) [28] . Our finding of expression in HUVECs suggests a role in vascular function which is supported by studies demonstrating miR-126 to be essential for angiogenesis and vascular remodelling under shear stress [29, 30] as well effects on vascular endothelial growth factor A (VEGFA) [31] Tryggestad et al. Page 8 Clin Sci (Lond). Author manuscript; available in PMC 2017 November 01.
abundance and the production of reactive oxygen species in HUVECs [32] . miR-126 is also expressed in the placenta [33] , and found to be decreased in pregnancies complicated by preeclampsia and fetal growth retardation [34, 35] .
Overexpression of miR-let-7 has demonstrated increased insulin production in response to glucose challenge in a mouse model and to impair glucose uptake in myotubes [20] . The miR-let-7 family has also been shown to inhibit oxidized LDL uptake and apoptosis of endothelial cells [36, 37] . In the placenta, let-7a has been shown to reduce cytotrophoblast proliferation [38] . Polymorphisms in let-7 have been associated with increased risk of T2DM [39] . miR-452 is dysregulated in wound healing in diabetic rodents [40] . Very little is known about miR-30c-5p as it relates to diabetes and obesity.
Although we have shown maternal diabetes effects changes in miRNA expression in the offspring, the exact mechanism for these changes remains unclear. Hepatic expression of miR-148a is increased when experimental animals are exposed to high-fat diets [21] , circulating levels of miR-130b are increased in in T2DM [41] , and both are positively correlated with BMI [25, 41, 42] . These data suggest that some feature of the metabolic syndrome, such as dysglycaemia, dyslipidaemia or increased oxidative stress, may be driving the increased expression of these miRNAs. In the case of miR-126-3p, expression is decreased in HUVECs exposed to high glucose [43] , the opposite of what would be expected if hyperglycaemia were responsible for our in vivo observations. Although there are other studies showing that hyperglycaemia or oxidative stress increase expression of specific miRNAs in cultured endothelial cells [44, 45] and trophoblasts [46] , none of these examined the seven miRNAs reported here.
Our finding of reduced AMPK in placental tissue of GDM offspring extends and supports the work of Martino et al. [47] who reported reduced AMPK (PRKAA1) mRNA in placentae of gestational diabetic pregnancies. Muralimanoharan et al. [48] reported a reduction in phosphorylated AMPK in placentae of women with GDM, but no change in total AMPK protein. The reason for this distinction from our study is unclear, but could reflect the much smaller number of subjects examined by Muralimanoharan et al. [48] , or the difference in sampling protocol (ours excluded maternal surface).
ACC is the rate-limiting step in fatty acid synthesis [49] . AMPK functions in the phosphorylation of ACC inactivating it and increasing fatty acid oxidation [50] . In the placenta samples, P-AMPK and P-ACC were decreased in placenta from diabetic mothers compared with control; however, the ratio of P-AMPK to AMPK was unchanged. This is expected to reduce fatty acid oxidation via decreased phosphorylation of ACC. BeWo cells were then transfected with anti-130b. Under serum-free conditions, total AMPKα1, P-AMPKα1 and P-ACC were all increased after inhibition of miR-130b in BeWo cells, suggesting increased fatty acid oxidative capacity. This also suggests that miR-130b effects fatty acid oxidation via the AMPK/ACC pathway. The reduction in P-ACC in BeWo cells transfected with miR-130b is consistent with a decrease in AMPK. The reduction in P-ACC suggesting decreased fatty acid oxidation potentially explains the decrease in fatty acid oxidation that is seen in infants born to mothers with diabetes.
Reduction in AMPK expression by the trophoblast has been demonstrated to decrease cell growth and glucose transport, leading to placenta dysfunction. Because miR-148a-3p is expressed by human placenta tissue [21] ; it may serve as a negative regulator of AMPKα1 and thereby contribute to abnormal placental function in response to maternal diabetes. However, in a single study of miRNA expression in placentae from GDM pregnancies, miR-130b-3p and miR-148a-3p were not among those differentially regulated by GDM [51] .
Although this could indicate that the GDM effect on these miRNAs is restricted to fetal endothelial cells, it may also reflect the mixed cellularity of placental tissue or the sensitivity of methods utilized to identify placental miRNAs postpartum.
We acknowledge certain limitations of our study. The first is that the sample size for the HUVECs was small with a predominance of males in the IGDM group. However, these initial studies serve as the entrée to the examination of miRNAs as mediators of the effects of maternal DM on offspring. Although a larger sample size may have identified additional differentially expressed miRNAs, the potential of the miRNAs we identified is supported by linkage to key metabolic pathways through our experiments as well as reports of others. The notion that sex explained the changes in these miRNAs was eliminated because there was no sex effect in the control group, but the possibility that the effect of maternal DM on the miRNA changes is restricted to male offspring cannot be excluded. Additionally, the placental samples were collected in a fashion that did not allow the analysis of mRNA or miRNA expression. The storage of the samples may also impair the analysis of phosphorylation. Finally, even though both our in vivo and in vitro experiments indicate regulation of AMPKα1 by miR-130b and miR-148a, the evidence that AMPKα1 mRNA is directly targeted by miR-130b and miR-148a in placental and endothelial cells remains circumstantial.
Our approach has several strengths. First, we measured miRNA abundance directly in HUVECs without prior culture or manipulation, thus examining the fetal cells first exposed to the diabetic milieu. Many human studies only sample plasma or an organ of mixed cellularity such as the placenta or evaluate cultured cells which may affect results. Secondly, we combined the less-biased miRNA array with a candidate-based approach in order to enhance identification of relevant miRNAs. Thirdly, we validated the influence of miR-130b and miR-148a on AMPKα1 not only in HUVECs but also in BeWo cells, supporting the potential for effects in the placenta. Finally, studies of placentae from mothers with GDM confirm an in vivo reduction in AMPKα1 abundance. In aggregate, these data strongly support the hypothesis that maternal diabetes influences AMPKα1 abundance via one or both of these miRNAs.
In summary, we have identified seven miRNAs that are altered by in utero exposure to GDM in infants of women whose dys-glycaemia was very well controlled by current standards, indicating that GDM, even when aggressively managed, leaves its mark on offspring. Decreased expression of AMPKα1 as a result of increased levels of miR-130b and miR-148a in infants born to mothers with diabetes may potentially explain the decrease in fat oxidation we previously observed in infants at 1 month of age and, if persistent, may predispose offspring to future metabolic disease. 
Abbreviations
CLINICAL PERSPECTIVES
• The chance of a child developing diabetes is much higher if the child is born to a mother with diabetes during pregnancy and is related, in part, to fetal exposure to a diabetic milieu. miRNAs are small non-coding RNA that regulate biologic processes, including those affecting energy metabolism. This study identified miRNAs differentially expressed in fetal tissues of the offspring of mothers with gestational diabetes mellitus and control mothers.
• The abundance of 7 distinct miRNAs was increased in HUVEC from infants born to mothers with diabetes. Two of the miRNAs, miR-130b and miR-148a, targeted AMPKα1, a key protein in energy metabolism, in in vitro experiments, and AMPKα1 protein abundance as well as its downstream targets was decreased in the placenta from infants born to mothers with diabetes.
• A decrease in AMPKα1 abundance mediated by changes in expression of miR-130b and miR-148a is a potential mechanism by which and offspring's future metabolic status may be influenced by maternal diabetes mellitus. Placentae from female IGDM and controls were collected and protein extracts were subjected to Western blot analysis. Detection of P-AMPKα1, P-ACC and total ACC (A) and its quantification (B, means ± S.E.M.), *P < 0.05, † P < 0.01, n = 13 in control group and n = 8 in IGDM group. Table 2 Characteristics of research subjects providing placenta samples Clin Sci (Lond). Author manuscript; available in PMC 2017 November 01.
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